10% of vimpat (lacosamide, lacamide) ® dry syrup is available in Japan

recently, Belgium'sPharmaceutical(http://giant UCB Japan sub-
company(http://UCB Japan Co and First Third Pharmaceuticals announced that 10 percent of the ® dry syrup of The Lacosamide (lacosamide) has been listed in Japanthe launch of the(http://of thisproduct will enhance the Vimpat ® product range in the Japanese market, making a greater contribution to the epileptic community and to thehealth care professionals in theMedical(http://10% of Vimpat®
Vimpat ® dry syrup is a new dosage form for Vimpat ® tablets 50mg and 100mg, suitable for treatment of partial seizure seclampsia (accompanied by or not secondary systemic seizures) in patients with epilepsyVimpat ® 10% of the dry syrup added to the water and mixed before the drug is administered, and is expected to improve medication compliance in patients who have difficulty swallowing Vimpat ® tablets, such as children and elderly patients with impaired swallowing function 　　Vimpat is a new type of NMDA receptor glycine site binding antagonists, belonging to a new class of functional amino acids, is a new dual mechanism of anticonvulsion drug (http:// Compared with other anti-epileptic drugs, Vimpat has the activity of regulating sodium ion channels, sodium ion channels in regulating nervous system activity, promoting the conduction between nerve cells has a very important function, by reducing the hyperactivity of sodium ion channels can control the activity of nerve cells to treat epilepsy 　　In China, Vimpat was approved in early December 2018 as an auxiliary treatment for partial seizures (accompanied or not accompanied by secondary systemic seizures) in adolescents and adults aged 16 and above 　　Currently, Vimpat is available in a variety of products, including tablets, oral syrups, injections, and dry syrups Vimpat injections are an alternative form of dosage in patients who are temporarily unable to take it orally